Our work shows folate improves atypical antipsychotic (AAP) CV effects in schizophrenia specifically improving endothelial functioning. Reducing AAP linked metabolic risks may help cut the 30 years of life lost within this population. Supplemental folate may be a cost effective and low risk method to reduce AAP CVD morbidity and mortality. Folate pharmacogenetics, allows us to mechanistically study AAP metabolic complications and develop personalized medicine within clinical practice. The objective of this project is to compare the effect of folate versus placebo on measures of the metabolic syndrome and CVD risk factors. We will evaluate metabolic laboratory components, and endothelial functioning, in schizophrenia patients receiving AAPs, taking into account pharmacogenetic differences related to folate metabolism. Our primary hypothesis is that folate will attenuate metabolic changes associated with AAP use, thereby contributing to improve endothelial functioning. Variation within the genes facilitating folate metabolism (methylenetetrahydrofolate reductase (MTHFR) and catechol-o-methyl transferase (COMT)) modulate these improvements. We have formulated this hypothesis based on our pilot data obtained during R01MH082784 showing AAPs increase metabolic syndrome risk due to an interaction with MTHFR and COMT. We performed an open-label 3-month folate supplement trial and found significant reductions in metabolic measures and significantly reduced the number of subjects meeting endothelial dysfunction criteria. These improvements were modulated through MTHFR and COMT.
The specific aims for this proposal are: 1) Evaluate the therapeutic effectiveness of folic acid supplementation (5mg/day) versus placebo for 16 weeks in schizophrenia subjects and measure sustainability of this effect 8 weeks after supplementation withdrawal, 2) Determine the role of MTHFR and COMT variants on endothelial functioning and metabolic improvements seen with folate supplementation. The innovative approach capitalizes upon a novel strategy to reduce AAP metabolic risks using a novel non-invasive endothelial functioning measurement as a biomarker. This allows for an overall CVD risk estimation compared to focusing on solely weight loss and glucose regulation. The inclusion of pharmacogenomics allows for potential innovative translation of personalized medicine outcomes into practice. Our expected outcomes will demonstrate folate's effectiveness in attenuating metabolic syndrome measures and improvements in endothelial functioning in AAP users with a randomized double blind longitudinal treatment design. Our follow up visit will allow for measurement of any sustained folate effects leading to future dose ranging studies. Successful completion of our pharmacogenetic analyses can be expected to provide a greater mechanistic understanding of AAP metabolic risks. The primary positive impact of our anticipated findings will be an evidence-based scientific framework for folate intervention development for AAP metabolic complications, which can be directly translated into clinical practice.
The public health relevance of this proposed research is that its successful completion can be expected to provide a cost effective intervention that can be used to significantly reduce the risk of development of cardiovascular problems for patients taking antipsychotic medications to treat their serious mental illness. Ultimately this will help t markedly improve quality of life for such patients, significantly enhancing their expected life spa and reduce costs to the health care system.
|Ward, Kristen M; Yeoman, Larisa; McHugh, Cora et al. (2018) Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy 38:638-650|
|Yao, Beier; Mueller, Savanna A; Grove, Tyler B et al. (2018) Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity. Bipolar Disord 20:60-69|
|Flowers, Stephanie A; Evans, Simon J; Ward, Kristen M et al. (2017) Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy 37:261-267|
|Ward, Kristen M; Kraal, A Zarina; Flowers, Stephanie A et al. (2017) Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. Pharmacotherapy 37:1122-1130|
|Hicks, J K; Sangkuhl, K; Swen, J J et al. (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102:37-44|
|Kraal, A Zarina; Ward, Kristen M; Ellingrod, Vicki L (2017) Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacol Bull 47:8-21|
|Grove, Tyler B; Tso, Ivy F; Chun, Jinsoo et al. (2016) Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. Psychiatry Res 243:198-206|
|Burghardt, Kyle J; Goodrich, Jacyln M; Dolinoy, Dana C et al. (2016) Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. Bipolar Disord 18:423-32|
|Grove, Tyler B; Burghardt, Kyle J; Kraal, A Zarina et al. (2016) Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders. Mol Neuropsychiatry 2:151-160|
|Flowers, Stephanie A; Ryan, Kelly A; Lai, Zongshan et al. (2016) Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. BMC Psychol 4:14|
Showing the most recent 10 out of 30 publications